2024-03-29T08:23:37Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_8873EB254E5F
2024-03-23T02:38:59Z
openaire
documents
urnserval
serval:BIB_8873EB254E5F
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
20458652
000282844500002
Taverna
C.
author
Bargetzi
M.
author
Betticher
D.
author
Gmür
J.
author
Gregor
M.
author
Heim
D.
author
Hess
U.
author
Ketterer
N.
author
Lerch
E.
author
Matthes
T.
author
Mey
U.
author
Pabst
T.
author
Renner
C.
author
article
review
2010
Swiss Medical Weekly
1424-3997
0036-7672
journal
140
w13054
Aged
Antineoplastic Agents/adverse effects
Antineoplastic Agents/therapeutic use
Biopsy, Needle
Bone Marrow/drug effects
Bone Marrow/pathology
Bone Marrow Transplantation
Boronic Acids/adverse effects
Boronic Acids/therapeutic use
Combined Modality Therapy
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance, Neoplasm
Evidence-Based Medicine
Humans
Middle Aged
Multiple Myeloma/diagnosis
Multiple Myeloma/drug therapy
Neoplasm Recurrence, Local/drug therapy
Neoplasm Recurrence, Local/pathology
Plasma Cells/drug effects
Plasma Cells/pathology
Pyrazines/adverse effects
Pyrazines/therapeutic use
Retreatment
Type="Geographic">Switzerland
Thalidomide/adverse effects
Thalidomide/analogs & derivatives
eng
60_published
Publication types: Comparative Study ; Consensus Development Conference ; Journal Article ; Research Support, Non-U.S. Gov't ; Review Publication Status: epublish
https://serval.unil.ch/notice/serval:BIB_8873EB254E5F
https://serval.unil.ch/resource/serval:BIB_8873EB254E5F.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_8873EB254E5F3
Copying allowed only for non-profit organizations